戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  gene expression, genotyping, proteomics and metabonomics.
2 h particular application in metabolomics and metabonomics.
3 ion of international reporting standards for metabonomics.
4 ne of the central approaches in the field of metabonomics.
5 bility PCR, 16S rRNA sequencing and 1(H) NMR metabonomics.
6 mbined with statistical analysis for further metabonomics analysis and biomarker identification.
7            591 patients participating in The Metabonomics and Genomics in Coronary Artery Disease (Ma
8                    Such collections arise in metabonomics and many other applications.
9  including metabolic profiling (metabolomics/metabonomics) and lipidomics, are making a significant i
10                                   By using a metabonomics approach (termed "NObonomics") for detailin
11 rofiles can be selectively amplified using a metabonomics approach based on the different NMR spectra
12 oney samples, a comparison of this classical metabonomics approach to one based on the use of the sel
13 olic subcompartments as well as conventional metabonomics concentration-based diagnostics.
14 arized CCA and correlation analyses of urine metabonomics data and 16S rRNA gene sequencing data to i
15 ciations between specific longitudinal urine metabonomics data and microbiome data in a diet-induced
16                                   Integrated metabonomics data assessment methodology should facilita
17 PLS allowed us to explore longitudinal urine metabonomics data in relation to the dietary groups, as
18 riptome and nuclear magnetic resonance-based metabonomics data.
19 ection and influence statistical analysis of metabonomics data.
20 ne-expression profiling, metaproteomics, and metabonomics, differences in microbial composition and f
21 y should facilitate translation of NMR-based metabonomics discovery of human disease biomarkers to cl
22 better approximate background variation in a metabonomics experiment is presented.
23 tegy combining pharmacokinetics, toxicology, metabonomics, genomics, and metagenomics to elucidate an
24                                              Metabonomics is an advancing field in systems biology, w
25                             Modern NMR-based metabonomics is elucidating contaminant toxicity and tox
26           Metabolite profiling (metabolomics/metabonomics) is a powerful means of assigning phenotype
27 nd cotton ball brands be characterized using metabonomics methodologies prior to initiating a metabon
28 nimals and show that it is possible to apply metabonomics methodology to this important class of biof
29 ma profiles generated by a key technology in metabonomics, NMR spectroscopy.
30 presents diagnostic potential for studies by metabonomics of mass-limited biopsies.
31                                              Metabonomics offers a posttranscriptional view of system
32 romatography/mass spectrometry (LC/MS) based metabonomics screening of urine has great potential for
33 nfluence the outcome of NMR- and LC/MS-based metabonomics studies of human infant urine.
34 d potentially influence NMR- and LC/MS-based metabonomics studies.
35 o identify biomarkers both in proteomics and metabonomics studies.
36 s, which are sometimes vitally important for metabonomics studies.
37 bonomics methodologies prior to initiating a metabonomics study to ensure that contaminant profiles a
38 ng an artificial data set and spectra from a metabonomics study.
39                                              Metabonomics techniques of data reduction and pattern re
40 se of nuclear magnetic resonance (NMR)-based metabonomics to search for human disease biomarkers is b
41                  In general, applications of metabonomics using biofluid NMR spectroscopic analysis f
42 ectra or mixtures of compounds, as in chiral metabonomics, where severe overlapping exists in proton